PF-Atlas › Clinical Trials › NCT05444257
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
VX-121/TEZ/D-IVA · Phase 3
Registry ID
NCT05444257
Phase
Phase 3
Status
Active, not recruiting
Drug / intervention
VX-121/TEZ/D-IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2022-11-08
About this trial
VX-121/TEZ/D-IVA is evaluated in NCT05444257, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Active, not recruiting.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05444257 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.